A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus

Transplantation

Volumn 84, Issue 11, 2007, Pages 1436-1442

  Hill, James A ^a   Hummel, Manfred ^b   Starling, Randall C ^c   Kobashigawa, Jon A ^d   Perrone, Sergio V ^e   Arizón, Josè M ^f   Simonsen, Svein ^g   Abeywickrama, Kamal H ^h   Bara, Christoph ⁱ  

^a UNIVERSITY OF FLORIDA   (United States)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e FLENI   (Argentina)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Azathioprine; Cytomegalovirus; Everolimus; Heart transplant; Proliferation signal inhibitor; Prophylaxis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; EVEROLIMUS;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GRAFT RECIPIENT; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INCIDENCE; LABORATORY TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SIROLIMUS; TIME FACTORS; TISSUE DONORS;

EID: 37349084974     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000290686.68910.bd     Document Type: Article

References (37)

1. Humar A, Gillingham KJ, Payne WD, et al. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68: 1879.
2. Pouteil-Noble C, Ecochard R, Landrivon G, et al. Cytomegalovirus infection-an etiological factor for rejection? Transplantation 1993; 55: 851.
3. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261: 3607.
4. Gratten MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561.
5. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741.
6. Soderberg-Naucler C, Emery VC. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 2001; 71: 24.
7. Hibberd PL, Snydman DR. Cytomegalovirus infection in organ transplant recipients. Infect Dis Clin North Am 1995; 9: 863.
8. Van der Bij W, Speich R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis 2001; 33: 32.
9. Rand KH, Pollard RB, Merigan TC. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med 1978; 298: 951.
10. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000; 13: 83.
11. Koskinen PK, Nieminen MS, Krogerus LA, et al. Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts. J Heart Lung Transplant 1993; 11: 724.
12. McGiffin DC, Savunen T, Kirklin JK, et al. Cardiac transplant coronary artery disease. J Thorac Cardiovsc Surg 1995; 109: 1081.
13. Everett JP, Hershberger RE, Norman DJ, et al. Prolonged cytomegalovirus infection with viremia ia associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant 1992; 11: 133.
14. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000 1; 95: 2240.
15. Eisen HJ, Tuzcu EM, Dorent R, et al., for the Everolimus B253 Study Group. Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. N Engl J Med 2003; 349: 847.
16. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: A meta-analysis. Transplantation 1998; 65: 641.
17. Neumayer HH, Paradis K, Korn A, et al. Entry-into-human study with the novel immunosuppressant SDZ Everolimus in stable renal transplant recipients. Br J Clin Pharmacol 1999; 48: 694.
18. Vitko S, Margreiter R, Weimar W, et al.; Everolimus B201 Study Group. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004 27; 78: 1532.
19. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
20. Shirali GS, Ni J, Chinnock RE, et al. Association of viral genome with graft loss in children after cardiac transplantation. N Eng J Med 2001; 344: 1498.
21. Geist LJ, Dai LY. Cytomegalovirus modulates interleukin-6 gene expression. Transplantation 1996; 62: 653.
22. Craigen JL, Grundy JE. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation 1996; 62: 1102.
23. Norday I, Muller F, Nordal KP, et al. Chemokines and soluble adhesion molecules in renal transplant recipients with cytomegalovirus infection. Clin Exp Immunol 2000; 120: 333.
24. Van Zanten J, de Leij L, Prop J, Harmsen MC. Human cytomegalovirus: A viral complication in transplantation. Clin Transplant 1998; 12: 145.
25. Rubin R. Infection in organ transplant recipients. In: Rubin RH, Young LS, eds. Clinical Approach to Infection in the Compromised Host, 3rd ed. New York and London: Plenum Medical Book Company, 1994: 629.
26. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110.
27. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
28. Nashan B, Moore R, Amiot P, et al. CHIB 201 International Study Group. Lancet 1997;350: 1193.
29. Kahan BD, Rajagopalan PR, Hall M, et al. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999;67: 276.
30. Mayer AD, Dmitrewski J, Squifflet J-P, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft refection. Transplantation 1997; 64: 436.
31. Gruber SA, Garnick J, Morawski K, et al. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant 2005; 19: 273.
32. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
33. Mathew TH, for the Tricontinental Mycophenolate Renal Transplantation Study Group. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Transplantation 1998; 65: 1450.
34. Sollinger HW, for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
35. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of refection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Eng J Med 2000; 243: 613.
36. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of myocphenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507.
37. Johnson RA, Wang X, Ma XL, et al. Human cytomegalovirus upregulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol 2001; 75: 6022.